Publication | Open Access

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

Breast OncologyMedicinePharmacologyN0332 Phase 2Breast CancerPharmacotherapyAnti-cancer AgentWeekly Irinotecan HydrochlorideCancer TreatmentOncology